
Science at Sanofi
Explore latest events, medical insights and trends.
Events
Stay up to date and register for the latest events and view webinar recordings.

Expanding the landscape of Type 2 inflammation
From shared pathways toward therapeutic innovation

Nirsevimab in Focus: Clinical Insights into RSV Protection
Join Professor Yung Chee Fu as he presents the compelling clinical evidence behind nirsevimab (Beyfortus), a breakthrough single-dose solution for RSV protection in all infants. Through comprehensive trial data, Prof. Yung demonstrates nirsevimab's remarkable 70-86% efficacy in preventing RSV-related hospitalizations across all infant populations. The presentation highlights how Nirsevimab provides extended protection beyond five months, making it particularly valuable for Singapore's year-round RSV season, while maintaining an excellent safety profile across all gestational ages.

Beyond the Trials: Nirsevimab's Real-World Evidence in Action
Join Dr. Juan Pablo Torres Torretti for an instructive presentation on the real-world implementation and impact of nirsevimab for RSV prevention. Drawing from groundbreaking data from Chile—the first Southern Hemisphere country to implement a nationwide nirsevimab immunization program—Dr. Torres reveals remarkable outcomes including 80-95% reduction in RSV hospitalizations and 85% reduction in PICU admissions. The presentation highlights Chile's successful strategy of protecting both newborns and infants under six months, achieving over 90% coverage rates with an excellent safety profile. Dr. Torres also shares comparative data from other countries including Spain's NIRSE-GAL study, demonstrating consistent effectiveness across different healthcare systems and providing compelling evidence for nirsevimab's role in transforming RSV prevention globally.

Demystifying Pompe Disease: Asia Pompe Expert Forum - Chapter 1: Introduction to Pompe Disease

European Academy of Allergy and Clinical Immunology (EAACI) Congress Highlights
13–16 June 2025, in Glasgow, Scotland.
Cutting-Edge Science
Discover medical insights and trends from trusted sources and key opinion leaders.

Real-Life Indirect Case Matched Comparison of Dupilumab and Tezepelumab on Airway Oscillometry

Nirsevimab in Focus: Clinical Insights into RSV Protection
Join Professor Yung Chee Fu as he presents the compelling clinical evidence behind nirsevimab (Beyfortus), a breakthrough single-dose solution for RSV protection in all infants. Through comprehensive trial data, Prof. Yung demonstrates nirsevimab's remarkable 70-86% efficacy in preventing RSV-related hospitalizations across all infant populations. The presentation highlights how Nirsevimab provides extended protection beyond five months, making it particularly valuable for Singapore's year-round RSV season, while maintaining an excellent safety profile across all gestational ages.

Beyond the Trials: Nirsevimab's Real-World Evidence in Action
Join Dr. Juan Pablo Torres Torretti for an instructive presentation on the real-world implementation and impact of nirsevimab for RSV prevention. Drawing from groundbreaking data from Chile—the first Southern Hemisphere country to implement a nationwide nirsevimab immunization program—Dr. Torres reveals remarkable outcomes including 80-95% reduction in RSV hospitalizations and 85% reduction in PICU admissions. The presentation highlights Chile's successful strategy of protecting both newborns and infants under six months, achieving over 90% coverage rates with an excellent safety profile. Dr. Torres also shares comparative data from other countries including Spain's NIRSE-GAL study, demonstrating consistent effectiveness across different healthcare systems and providing compelling evidence for nirsevimab's role in transforming RSV prevention globally.

Demystifying Pompe Disease: Asia Pompe Expert Forum - Chapter 1: Introduction to Pompe Disease

Updated Evidence from the EVEREST Phase 4 Trial
First, prospective, head-to-head data comparing Dupilumab and Omalizumab in CRSwNP and asthma patients.
Please log in or register to continue reading.
Login For Healthcare Professionals
HCP Verification Required
We are in the midst of verifying your registration. You will receive an email confirmation to access Campus Sanofi once your verification is complete.
RESEND SUCCESS
Please check you email for verification emali.
Restricted Content
You do not have the correct verified role to view this content.
You are almost set!
Success
Thank you for registering. Please validate your email by clicking on the link in the email sent to you. Once your registration has been validated, you will receive a confirmation email to log in to Campus Sanofi.
Patient-Video

Request-form
